AZD3463 ALK/IGF1R Inhibitor: A Next-Gen Oral Agent for Neuroblastoma

Executive Summary: AZD3463 is an orally administered small molecule that selectively inhibits ALK and IGF1R with a Ki of 0.75 nM, showing robust suppression of neuroblastoma cell proliferation in vitro and in vivo [APExBIO product page]. It overcomes resistance to first-generation ALK inhibitors, including crizotinib, particularly in cells with F1174L or D1091N ALK mutations [see detailed mechanism]. By blocking the ALK-mediated PI3K/AKT/mTOR pathway, AZD3463 induces both apoptosis and autophagy in neuroblastoma models (Labrèche et al., 2021). It exhibits synergy with chemotherapeutic agents such as doxorubicin and temozolomide, providing a rational combination strategy. AZD3463’s solid-state properties and DMSO solubility parameters facilitate integration into preclinical workflows.

Biological Rationale

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase highly expressed in neurons and frequently mutated or upregulated in neuroblastoma. Activating mutations such as F1174L and D1091N in ALK confer aggressive tumor phenotypes and resistance to first-line inhibitors. The PI3K/AKT/mTOR pathway, downstream of ALK, is a master regulator of tumor cell survival and proliferation in multiple malignancies, including breast cancer and neuroblastoma (Labrèche et al., 2021). IGF1R is another receptor tyrosine kinase implicated in oncogenic signaling and therapeutic resistance. Dual inhibition of ALK and IGF1R has been hypothesized—and empirically validated—to suppress compensatory signaling that sustains tumor growth.

Mechanism of Action of AZD3463 ALK/IGF1R inhibitor

AZD3463, catalogued as A8620 by APExBIO, is designed to bind the kinase domains of both ALK and IGF1R. Its Ki value of 0.75 nM indicates high affinity binding. The compound blocks ALK autophosphorylation, thereby inhibiting downstream PI3K/AKT/mTOR signaling. This leads to reduced phosphorylation of AKT (Ser473) and downstream effectors, ultimately decreasing tumor cell survival signals. In neuroblastoma models, AZD3463 induces apoptotic markers (e.g., cleaved caspase-3) and autophagy-related proteins (e.g., LC3B-II), particularly at concentrations ranging from 5 to 50 μM [APExBIO]. Importantly, it retains efficacy in cells with ALK activating mutations such as F1174L and D1091N, which are associated with resistance to crizotinib. Combination with DNA-damaging chemotherapeutic agents further enhances cytotoxicity, supporting rational polytherapy approaches.

Evidence & Benchmarks

• AZD3463 inhibits neuroblastoma cell viability in vitro in a dose-dependent manner at 5–50 μM, inducing caspase-dependent apoptosis (APExBIO, product page).
• It exhibits nanomolar affinity (Ki = 0.75 nM) for ALK kinase, enabling selective pathway inhibition (APExBIO, product page).
• AZD3463 overcomes crizotinib resistance by suppressing proliferation in ALK-mutant neuroblastoma cell lines (F1174L, D1091N) (see comparative analysis).
• In vivo, intraperitoneal dosing at 15 mg/kg daily for two days significantly reduces tumor growth in orthotopic neuroblastoma xenograft models (APExBIO, product page).
• Dual inhibition of ALK and IGF1R suppresses compensatory PI3K/AKT/mTOR signaling, a pathway also shown to regulate periostin expression and tumor aggressiveness (Labrèche et al., 2021, Fig. 4).
• Synergistic cytotoxicity is observed when AZD3463 is combined with doxorubicin or temozolomide, supporting combination regimens in preclinical models (APExBIO, product page).

For additional mechanistic insights and comparative data, see this review clarifying AZD3463's activity in crizotinib-resistant settings—this article extends those findings by detailing solubility and workflow optimization parameters.

Applications, Limits & Misconceptions

AZD3463 is primarily indicated for preclinical research in ALK-driven cancers, notably neuroblastoma. Its dual ALK/IGF1R inhibition profile makes it a tool for probing compensatory signaling and resistance mechanisms. Applications include:

• Evaluating apoptosis and autophagy induction in neuroblastoma cell lines, including those with ALK activating mutations.
• Assessing synergistic cytotoxicity with standard-of-care chemotherapeutics.
• Modeling resistance mechanisms to first-generation ALK inhibitors such as crizotinib.
• Interrogating PI3K/AKT/mTOR pathway dependency in tumor models.

Common Pitfalls or Misconceptions

• AZD3463 is not a selective ALK inhibitor; it also targets IGF1R, which may confound pathway-specific assays.
• It is not water- or ethanol-soluble; improper solvent use may result in precipitation and loss of activity.
• Long-term storage of solutions, even in DMSO at -20°C, is not recommended due to potential degradation.
• The compound has not been validated for clinical use and should not be interpreted as a therapeutic agent in humans.
• Effectiveness outside ALK- or IGF1R-driven malignancies has not been established.

For expanded discussion of applications in stem cell and regenerative research, see this article, which this dossier updates with new solubility and in vivo dosing data.

Workflow Integration & Parameters

AZD3463 is supplied as a solid (MW 448.95, C24H25ClN6O) by APExBIO. It is insoluble in water and ethanol but readily dissolves in DMSO at ≥11.22 mg/mL. For optimal dissolution, stock solutions should be warmed or sonicated. Store aliquots at -20°C for up to several months, but avoid repeated freeze-thaw cycles and long-term storage of working dilutions. In vitro assays should use DMSO as the vehicle control, with final concentrations not exceeding 0.1% v/v. In vivo, AZD3463 has been used at 15 mg/kg via intraperitoneal injection in mouse xenograft models. Always verify batch purity and refer to APExBIO’s technical datasheet (AZD3463 ALK/IGF1R inhibitor).

For workflow comparisons and troubleshooting, see this benchmark summary, which this article augments by detailing compound handling and solubility nuances for consistent results.

Conclusion & Outlook

AZD3463, as supplied by APExBIO, is a next-generation oral dual ALK/IGF1R inhibitor with demonstrated efficacy in preclinical models of neuroblastoma, especially those harboring resistance-conferring ALK mutations. By targeting the PI3K/AKT/mTOR axis, AZD3463 enables robust apoptosis and autophagy induction while supporting rational combination approaches with chemotherapeutics. Its integration into cancer research workflows is facilitated by clear solubility and storage guidelines. Further studies are warranted to expand the translational potential of this compound for ALK-driven and possibly IGF1R-dependent malignancies.